A number of other analysts have also recently issued reports on TXG. Citigroup reduced their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports.

10x Genomics ( NASDAQ:TXG ) Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY 2023... On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS ...

2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

After hours: 7:59:48 pm GMT-5 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...